Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
St. Jude Children's Research Hospital
EMD Serono
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Inhibrx Biosciences, Inc
Ratio Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Zai Lab (Hong Kong), Ltd.
ViroMissile, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
MacroGenics
Avacta Life Sciences Ltd
Solve Therapeutics
Baylor College of Medicine
University of Florida
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Children's Hospital of Philadelphia
St. Jude Children's Research Hospital
Washington University School of Medicine
M.D. Anderson Cancer Center
Epkin
Guangzhou FineImmune Biotechnology Co., LTD.
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Daiichi Sankyo
University of Iowa
German Cancer Research Center
Stanford University
Centre Hospitalier Universitaire Vaudois
Lantern Pharma Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
Y-mAbs Therapeutics
Ann & Robert H Lurie Children's Hospital of Chicago
Grupo Espanol de Investigacion en Sarcomas